Breast cancer and hair loss
- Medical Review: Dianne L. Hyman, MSN, RN, OCN
Breast cancer itself does not cause hair loss, but some breast cancer treatments can. If you’re facing breast cancer treatment and are concerned about hair loss, you’re not alone. For many people, hair loss can be one of the most emotionally challenging parts of breast cancer treatment. Your hair is part of who you are, and losing it can feel like a loss of control. But there are ways to prepare for and even reduce the risk of hair loss caused by treatment.
Treatment-related hair loss happens for different reasons. Chemotherapy kills rapidly dividing cells, including hair cells. Hormonal therapies block or lower estrogen, and that can cause hair thinning for some people. Radiation therapy can cause hair loss in the area receiving radiation.
It’s important to know that hair loss doesn’t happen to every person with every treatment, and the hair loss people experience from breast cancer treatments is almost always temporary.
Breast cancer treatments & hair loss
Different treatments can cause hair thinning or loss in different ways:
Chemotherapy
Chemotherapy kills quickly dividing cells, such as cancer cells. But some healthy cells also divide quickly. Hair follicles, for instance, are among the most quickly growing cells in the body, so they are more likely to be affected by chemotherapy. How a chemotherapy drug affects hair often depends on the drug. Not all chemotherapies cause total hair loss. Some cause the hair to thin; others will only barely affect hair. Some chemotherapies affect hair all over the body, such as eyebrows, eyelashes, and pubic hair. The timing and dose of the chemotherapy can also be a factor in how your hair will be affected. Ask your doctor about what you can expect from the recommended chemotherapy and treatment schedule.
For some people, hair may start to grow back during treatment. Usually, hair starts to grow back one to three months after chemotherapy ends. It could be a different color or texture than it was before. Sometimes it stays that way. In other cases, hair returns to exactly the way it was before treatment.
It’s important to know that permanent hair loss is not usually a chemotherapy side effect, but it does happen. The taxane chemotherapies docetaxel (Taxotere) and paclitaxel (Taxol) have been reported to cause permanent hair loss for some people. Research shows that this is more likely with docetaxel. Research has also shown that scalp cooling can reduce the risk of temporary and permanent hair loss for people undergoing chemotherapy, including taxane chemotherapy. If chemotherapy is part of your treatment plan, ask your doctor if there’s an option that does not have a risk of causing permanent hair loss. You may also want to ask about scalp cooling resources, and connect with others who’ve undergone chemotherapy to learn about their experiences.
Hormonal therapy
Hormonal therapy treatments can cause mild to moderate hair loss or thinning because they reduce or block estrogen, which helps hair to grow. Hormonal therapy includes:
- Aromatase inhibitors, tamoxifen, and fulvestrant (Faslodex)
- Ovarian suppression medicines such as goserelin (Zoladex) and leuprolide (Lupron)
- Oophorectomy (surgical removal of the ovaries) for premenopausal women at high risk of developing breast and ovarian cancer because of a BRCA1 or BRCA2 genetic mutation
Hair loss or thinning from hormonal therapy is not as significant as it can be with chemotherapy. With most hormonal therapy medicines, the impact on your hair will continue as long as you are taking the medicine. Hormonal therapy combined with the stress of a breast cancer diagnosis can affect the degree of hair thinning or loss. Not getting enough nutrients, as well as family history and genetic predisposition to hair thinning, can also have an impact.
There are medicines that can help treat hair thinning and loss caused by hormonal therapy and other treatments. Ask your doctor if there are safe options for you. You can also ask about whether your cancer center has a dietician on staff to make sure you’re getting the nutrients that support hair growth.
It’s important to know that hair loss doesn’t happen to every person with every treatment, and the hair loss people experience from breast cancer treatments is almost always temporary.
Targeted therapy
Targeted therapy for breast cancer do not cause complete hair loss, but they may cause hair to become thinner, curlier, or drier than usual. As with other drugs, you can expect the effect on your hair to last for the time that you take the drug. Not all targeted therapies cause hair thinning or hair loss. Targeted therapies that may cause hair loss include medicines such as pertuzumab (Perjeta), lapatinib (Tykerb), palbociclib (Ibrance), ribociclib (Kisqali), alpelisib (Piqray), talazoparib (Talzenna), and abemaciclib (Verzenio). If targeted therapy is part of your treatment plan, ask your doctor if the therapy being recommended for you causes hair loss.
Immunotherapy
Immunotherapy uses the body’s own defense system to fight cancer. The immunotherapy drug pembrolizumab (Keytruda) can cause areas of hair loss. This can happen many weeks to three months after beginning treatment. These effects usually last for the time you are taking the drug.
Radiation therapy
Radiation therapy directs high-energy x-rays to a specific part of the body to kill cancer cells. While chemotherapy can sometimes cause hair loss all over the body, radiation therapy causes hair loss only on the specific part of the body that is being treated. If the radiation is being directed to the breast area, for example, you won’t lose hair on your head. If radiation is being directed at lymph nodes under your arm, you may temporarily lose underarm hair.
Wherever radiation is being directed, if hair loss happens, it can begin about two to three weeks after your first session. Hair usually grows back in three to six months. If the radiation is delivered in high doses, it’s possible that hair regrowth to the area may be thinner, or that it may not return, after radiation is finished. Talk with your doctor about how radiation therapy may impact the hair on the area of treatment.
What are the symptoms of hair loss?
Hair loss will not hurt, although you may feel some scalp tenderness before hair falls out. If you are being treated with a chemotherapy drug that causes significant hair loss, such as doxorubicin (Adriamycin), hair usually falls out two to four weeks after beginning treatment. With other chemotherapy drugs, hair may not fall out until one or two months into treatment. Different chemotherapies, and schedules for receiving it, will affect this timetable. Ask your doctor what to expect for your particular situation.
When hair begins to fall out, you may lose hair in the shower or notice clumps of hair on your pillow or in your comb or brush. For many people, chemotherapy causes hair to fall out at the center or crown of the head first, and hair on the sides of your head may not fall out until later. All your body hair, including your eyelashes, eyebrows, and pubic hair, may eventually be affected.
Hair thinning or loss caused by hormonal therapy happens differently than it can with chemotherapy. It’s usually milder and tends to affect the front of the hairline, and sometimes the crown of the head.
If you are being treated with immunotherapy or targeted therapy, talk with your care team about what to expect with hair thinning, as symptoms can vary depending on the specific treatment.
Managing hair loss
The first step in managing hair thinning or hair loss is to understand how likely it is with your treatment plan. Here are some questions you can ask your care team:
- Does the treatment you are recommending cause hair thinning or hair loss?
- How much hair loss occurs with this treatment?
- What can I do to reduce or manage hair loss?
- When does hair loss typically happen with this treatment?
- When should I expect my hair to grow back?
If your treatment causes hair thinning or loss, it’s important to do what feels best to you, helps you feel confident, and makes you comfortable. With the total hair loss that can happen as a result of some chemotherapies, many people find it empowering to shave their heads, or cut their hair very short, before it falls out. Others may wait until a lot of hair has fallen out before cutting or shaving it. Gradually cutting hair shorter over the course of a few days or weeks helps some people ease into the idea of having no hair.
Here are some ways to be gentle to your hair during cancer treatment:
- Use mild shampoo
- Use soft-bristle hairbrushes
- Use low heat if you use a hair dryer
- Avoid using brush rollers
- Avoid dyeing or perming your hair
- Use a satin pillowcase
If you choose to cover your head when hair falls out, you may want to explore your options ahead of time. You can choose a wig that resembles your natural hair or one that gives you a new look. Other options include hats, caps, or scarves. Many women alternate between all of these.
Heat escapes from the tops of our heads. Without hair, you may feel chilly at times. If you don’t want to cover your head, it is perfectly fine to go bald — just remember to use sunscreen, and have a hat on hand to make sure you’re warm enough.
You may have heard of scalp cooling, a therapy that helps some people keep some or all of their hair during chemotherapy. Scalp cooling involves wearing a cooled headpiece during chemotherapy sessions. Since you’re lowering the temperature of your hair follicles and scalp, the blood flow to the area is slowed. As a result, hair follicles are less exposed to the chemotherapy medicines.
There are two available scalp cooling methods:
- Refrigerated, machine-based scalp cooling systems that keep the cap cold during your treatment session
- Cold caps kept in a cooler on dry ice
Research shows that scalp cooling helps some people keep their hair throughout chemotherapy. Learn more about scalp cooling.
Some research has shown that minoxidil (often sold as Rogaine) can help hair grow back faster after chemotherapy. If you’re interested in trying minoxidil, ask your doctor to confirm that it will be safe for you.
While you may hear about some women using hormone replacement therapy (HRT) to help with hair thinning related to reduced hormone levels, HRT has been shown to increase the risk of breast cancer and is not recommended for people who’ve been diagnosed.
Managing ongoing hair thinning
If you’re facing ongoing treatment, or your hair has not recovered from treatment, it may make sense to see a dermatologist. Some cancer centers have specialists called oncodermatologists who focus on treatment-related changes to the hair, nails, and skin. Even if your hospital does not have an oncodermatologist, most dermatology specialists will understand some of these issues. Ask your oncologist for a referral to a dermatologist who has experience working with hair loss related to cancer treatment. Share the dermatologist’s recommendations with your doctor to make sure they are safe for you.
Dealing with the emotional impact of hair loss
Hair loss can be upsetting for anyone of any gender. If your hair means a lot to you, losing it can be painful. Even if you’ve never felt that your hair was an important part of who you are, losing it can still be distressing.
Hair loss also makes the issue of having cancer more public. For many people, it can bring up feelings of vulnerability and unwanted exposure.
If emotions about hair loss are interfering with your daily life, it can help talk to a mental health professional. Ask your healthcare team to recommend a licensed professional counselor or therapist who specializes in helping women with breast cancer. In-person support groups or online communities may also bring you comfort. It can be reassuring to meet others who know what it’s like, and to know you’re not alone.
Visit these pages to learn more about supportive resources:
Related videos
View allStay connected
Sign up to receive emotional support, medical insight, personal stories, and more, delivered to your inbox weekly.
- 3-dimensional radiation therapy
- 4-hydroxytamoxifen
- ablation
- abnormal
- Abraxane
- absolute risk
- AC regimen
- AC-T regimen
- AC-T-T regimen
- AC-Taxol regimen
- AC-TH regimen
- accelerated partial-breast irradiation
- action study
- acupoint
- acupressure
- acupuncture
- acupuncture needle
- acupuncture point
- acupuncture point injection
- acupuncturist
- acustimulation
- acute
- acute pain
- adenocarcinoma
- adenopathy
- adenosis
- adjunct agent
- adjunct therapy
- adjunctive therapy
- adjuvant therapy
- advance directive
- advanced practice nurse
- adverse effect
- aerobic exercise
- agent study
- aggravating factor
- aggressive
- AJCC staging system
- Alkeran
- alkylating agent
- Allegra
- allopathic medicine
- alopecia
- amifostine
- aminoglutethimide
- amitriptyline
- anabolic steroid
- analgesic
- anaplastic
- anastrozole
- ancillary test
- anemia
- anesthesia
- anesthesiologist
- angiogenesis
- angiogenesis inhibitor
- antagonist
- anthracycline
- anti-anxiety medicine
- anti-idiotype vaccine
- anti-inflammatory
- antibody-dependent cellular cytotoxicity
- antibody therapy
- anticachexia
- anticancer antibiotic
- anticancer therapy
- anticonvulsant
- antidepressant
- antiemetic
- antiestrogen
- antifolate
- antigen-presenting cell vaccine
- antihormone therapy
- antimetabolite
- antimitotic agent
- antineoplastic
- antitumor
- anxiety
- anxiolytic
- Anzemet
- APN
- apocrine gland
- apoptosis
- aprepitant
- areola
- Aromasin
- aromatase inhibitor
- aromatherapy
- arthralgia
- ascites
- aspirate
- aspiration
- assay
- asthenia
- asymptomatic
- atypia
- atypical ductal hyperplasia
- atypical hyperplasia
- atypical lobular hyperplasia
- avoidance
- axillary lymph node
- axillary lymph node dissection
- BAK gel
- balloon catheter radiation
- baseline
- behavior modification
- best practice
- BI-RADS
- Biafine cream
- bias
- bilateral
- bilateral breast cancer
- bilateral prophylactic mastectomy
- bilateral salpingo-oophorectomy
- biofeedback
- biologic
- biopsy
- biopsy specimen
- biotherapy
- bisphosphonate
- bisphosphonate-associated osteonecrosis
- blinded study
- blood-brain barrier
- blood-brain barrier disruption
- blood cell count
- blood chemistry study
- board certified oncology pharmacy specialist
- body image
- body mass index
- bolus dose
- bone density
- bone metastasis
- bone mineral density scan
- bone scan
- bone-seeking radioisotope
- brachytherapy
- brain metastasis
- BRCA1
- BRCA2
- BRCAPro
- breast carcinoma in situ
- breast-conserving surgery
- breast density
- breast duct
- breast duct endoscopy
- breast lobe
- breast lobule
- breast reconstruction
- breast self-exam
- Brief Pain Inventory
- cachexia
- CAF regimen
- calcification
- cancer vaccine
- candidiasis
- capecitabine
- carboplatin
- carcinogen
- carcinoma
- carcinoma in situ
- carcinomatous meningitis
- carcinosis
- carcinostatic
- cardiotoxicity
- caregiver
- carmustine
- case-control study
- case report
- case series
- CAT scan
- CBC
- cell
- cell-cycle regulation
- cell proliferation
- central nervous system
- central nervous system metastasis
- central nervous system prophylaxis
- central venous access catheter
- cetuximab
- cevimeline
- chaplain
- charged-particle radiation therapy
- chemoembolization
- chemoimmunotherapy
- chemoprevention
- chemoprevention study
- chemoprotective
- chemoradiation
- chemosensitivity
- chemosensitivity assay
- chemosensitizer
- chemotherapeutic agent
- chemotherapy
- chest wall
- chest X-ray
- Chinese meridian theory
- chronic
- chronic pain
- cisplatin
- Claus model
- clergy
- clinical
- clinical breast exam
- clinical practice guidelines
- clinical researcher
- clinical resistance
- clinical series
- clinical stage
- clinical staging
- clinical study
- clinical trial
- clinician
- clodronate
- CMF regimen
- cognition
- cognitive behavior therapy
- cognitive therapy
- cohort
- cohort study
- coinsurance
- combination chemotherapy
- comedo carcinoma
- comfort care
- Coming Out
- Community Advisory Board
- comorbidity
- compassionate use trial
- complementary and alternative medicine
- complementary medicine
- complete metastasectomy
- complete remission
- complete response
- complex decongestive therapy
- compliance
- complication
- compression garment
- computed tomography scan
- concomitant
- concurrent therapy
- condition
- consolidation therapy
- constitutional acupuncture
- continuum of care
- contract research organization
- contraindication
- contralateral
- contrast material
- control group
- controlled clinical trial
- controlled study
- conventional medicine
- conventional therapy
- copayments
- cope
- coping skills
- core biopsy
- core needle biopsy
- corticosteroid
- counseling
- COX inhibitor
- cryoablation
- cryopreservation
- cryosurgery
- CT scan
- cultural competency
- cumulative dose
- cumulative exposure
- cure
- cutaneous
- cutaneous breast cancer
- cyclophosphamide
- cyclosporine
- CYP2D6 inhibitor
- cystosarcoma phyllodes
- cytopenia
- cytotoxic
- cytotoxic chemotherapy
- Cytoxan
- Data and Safety Monitoring Board
- DCIS
- de novo
- debulking
- deductible
- definitive surgery
- definitive treatment
- dehydration
- denosumab
- depression
- diagnosis
- diagnostic mammogram
- diagnostic procedure
- diagnostic technique
- diagnostic trial
- diameter
- diarrhea
- diaziquone
- DIEP flap
- dietary counseling
- dietary supplement
- dietitian
- differentiation
- diffuse
- digital mammography
- diphenhydramine
- discharge
- disease progression
- disease-specific survival rate
- distant cancer
- distant metastasis
- Distant recurrence
- distress
- DNR order
- docetaxel
- dolasetron
- dose
- dose-dense chemotherapy
- dose-dependent
- dose-limiting
- dose-rate
- double-blinded
- doxorubicin
- drain
- dronabinol
- droperidol
- drug interaction
- drug resistance
- drug therapy
- drug tolerance
- duct
- ductal carcinoma
- ductal carcinoma in situ
- ductal lavage
- duloxetine
- durable power of attorney
- dysfunction
- dysgeusia
- dyspepsia
- dyspnea
- early menopause
- early-stage breast cancer
- edema
- EEG biofeedback
- efficacy
- Eklund displacement views
- electroacupuncture
- electron beam
- eligibility criteria
- Ellence
- emesis
- emetic
- endocrine
- endocrine therapy
- endpoint
- energy healing
- enteral nutrition
- epidemiology
- epirubicin
- ER+
- ER-
- ER
- ER-PR-HER2/neu-
- eribulin mesylate
- erythema
- estradiol
- estrogen
- estrogen blocker
- estrogen receptor
- estrogen receptor-negative
- estrogen receptor-positive
- estrogen receptor test
- estrogen replacement therapy
- etanidazole
- etidronate
- everolimus
- Evista
- excision
- excisional biopsy
- exemestane
- expanded access trial
- experimental
- extranodal
- false-negative test result
- false-positive test result
- familial cancer
- family medical history
- Faslodex
- fast-neutron beam radiation
- fatigue
- FDA
- febrile neutropenia
- FEC regimen
- Femara
- fertility
- fexofenadine
- fibroadenoma
- fibrocystic breast changes
- fiducial marker
- film mammography
- fine-needle aspiration biopsy
- first-degree relative
- first-line therapy
- five-year survival rate
- fluorouracil
- fluoxetine
- FNA biopsy
- focal
- Food and Drug Administration
- Fosamax
- fractionation
- fulvestrant
- functional magnetic resonance imaging
- gadolinium
- Gail model
- gallium scan
- gamma irradiation
- Gamma Knife therapy
- gamma ray
- Gelclair
- gemcitabine
- gene
- gene expression profile
- gene therapy
- general anesthesia
- generalized anxiety disorder
- generic
- genetic
- genetic counseling
- genetic marker
- genetic marker of susceptibility
- genetic predisposition
- genetic profile
- genetic susceptibility
- genetic testing
- genetic testing
- genetics
- genome
- genome-wide association study
- genomic profile
- genomic test
- genomics
- gland
- Good Clinical Practice
- goserelin
- grade
- grading
- granisetron
- gross description
- Halaven
- hazard ratio
- healing touch
- Health Insurance Portability and Accountability Act
- healthcare provider
- healthcare proxy
- healthy control
- helical computed tomography
- HER2/neu
- Herceptin
- hereditary
- hereditary mutation
- heteronormative
- high-dose chemotherapy
- high-dose radiation
- high-energy proton therapy
- high grade
- high-risk cancer
- HIPPA
- histologic examination
- histology
- historic cohort study
- historical control subject
- homeopathic medicine
- hormonal therapy
- hormone
- hormone receptor
- hormone receptor test
- hormone replacement therapy
- hormone responsive
- hormone therapy
- hospice
- hot flash
- human epidermal growth factor receptor 2
- human participant protection regulations
- hydroxydaunorubicin
- hyperalimentation
- hypercalcemia
- hyperfractionated radiation therapy
- hyperfractionation
- hyperplasia
- hypersensitivity
- hypofractionated radiation therapy
- hypofractionation
- hypoxia
- ibandronate
- ibuprofen
- idiopathic
- image-guided radiation therapy
- imaging
- imaging procedure
- immune adjuvant
- immune function
- immune response
- immune system
- immune system tolerance
- immunization
- immunoassay
- immunocompromised
- immunodeficiency
- immunohistochemistry
- immunology
- immunomodulation
- immunosuppression
- immunotherapy
- implant
- implant displacement views
- implant radiation therapy
- implantable pump
- in network
- in situ
- incidence
- incision
- incisional biopsy
- indication
- indolent
- induction therapy
- infection
- infertile
- infertility
- infiltrating breast cancer
- infiltrating ductal carcinoma
- inflammation
- inflammatory breast cancer
- informed consent
- infusion
- ingestion
- inherited
- iniparib
- injection
- inoperable
- insomnia
- Institutional Review Board
- intensification therapy
- intensity-modulated radiation therapy
- interfering thought
- internal mammary lymph nodes
- internal radiation therapy
- International Unit
- internist
- interstitial radiation therapy
- intervention
- intervention group
- intra-arterial
- intracarotid infusion
- intradermal
- intraductal breast papilloma
- intraductal carcinoma
- intrahepatic
- intrahepatic infusion
- intramuscular
- intramuscular injection
- intraoperative radiation therapy
- intraoperative ultrasound
- intratumoral
- intravasation
- intravenous
- intravenous infusion
- intravenous injection
- intrusive thought
- intrusive thoughts
- invasive breast cancer
- invasive cancer
- invasive procedure
- investigational
- investigator
- ionizing radiation
- ipsilateral
- IRB
- irradiated
- irradiation
- irreversible toxicity
- ixabepilone
- joint pain
- Karnofsky Performance Status
- laboratory test
- lapatinib
- laser
- laser surgery
- laser therapy
- lassitude
- late effects
- late-stage cancer
- latent
- laxative
- LEEP
- legal aid organization
- lesion
- lethargy
- letrozole
- leukopenia
- levels of evidence
- Lexapro
- libido
- lidocaine
- ligation
- linac
- linear accelerator
- lipoma
- lisofylline
- liver metastasis
- liver scan
- living will
- lobaplatin
- lobe
- lobectomy
- lobular carcinoma
- lobular carcinoma in situ
- lobule
- local anesthesia
- local cancer
- local therapy
- localization
- localized
- locally advanced cancer
- locally recurrent cancer
- lomustine
- loop electrosurgical excision procedure
- loop excision
- lorazepam
- low grade
- lubricant
- lumbar puncture
- lumpectomy
- lung metastasis
- luteinizing hormone-releasing hormone agonist
- lymph
- lymph gland
- lymph node
- lymph node dissection
- lymph node drainage
- lymph node mapping
- lymph vessel
- lymphadenectomy
- lymphadenopathy
- lymphangiogram
- lymphangiography
- lymphatic basin
- lymphatic fluid
- lymphatic mapping
- lymphatic system
- lymphatic vessel
- lymphedema
- lymphography
- lymphoscintigraphy
- Lyrica
- lytic lesion
- macrocalcification
- magnetic resonance imaging
- magnetic resonance perfusion imaging
- magnetic resonance spectroscopic imaging
- mainstream medicine
- maintenance therapy
- male breast cancer
- malignancy
- malignant
- malignant pleural effusion
- malnutrition
- mammary
- mammary dysplasia
- mammary gland
- mammogram
- mammography
- MammoSite
- Mammotome
- mantle field
- MAO inhibitor
- margin
- marker
- mass
- massage therapy
- mastectomy
- mastitis
- maternal
- maximum tolerated dose
- mean survival time
- measurable disease
- medial supraclavicular lymph node
- median
- median survival time
- Medicaid
- medical castration
- medical device
- medical nutrition therapy
- medical oncologist
- Medicare
- medicine
- medullary breast carcinoma
- mega-voltage linear accelerator
- megestrol
- melphalan
- meningeal metastasis
- menopause
- menorrhagia
- menstrual cycle
- menstrual period
- menstruation
- mental health
- mental health counselor
- meridian
- mesna
- meta-analysis
- metallic
- metastasectomy
- metastasis
- metastasize
- metastatic
- methotrexate
- metoclopramide
- metronomic therapy
- microcalcification
- micrometastasis
- microscopic
- milk duct
- mind/body exercise
- mindfulness relaxation
- Miraluma test
- mitigate
- modified radical mastectomy
- molecular marker
- molecular medicine
- molecular risk assessment
- molecularly targeted therapy
- monoamine oxidase inhibitor
- monoclonal antibody
- morbidity
- mortality
- MRI
- MRSI
- MTD
- mTOR
- mucositis
- multicenter study
- multicentric breast cancer
- multidisciplinary
- multidisciplinary opinion
- multidrug resistance
- multidrug resistance inhibition
- multifocal breast cancer
- music therapy
- mutation
- mutation carrier
- myalgia
- myelosuppression
- nanoparticle paclitaxel
- narcotic
- National Cancer Institute
- National Center for Complementary and Alternative Medicine
- National Institutes of Health
- natural history study
- naturopathy
- nausea
- NCCAM
- NCI
- NCI clinical trials cooperative group
- needle biopsy
- needle localization
- needle-localized biopsy
- negative axillary lymph node
- negative test result
- neoadjuvant therapy
- neoplasm
- nerve
- nerve block
- neurocognitive
- neurologic
- neuropathy
- neurotoxicity
- neurotoxin
- neutropenia
- NIH
- nipple
- nipple discharge
- nitrosourea
- NMRI
- node-negative
- node-positive
- nodule
- nonblinded
- nonconsecutive case series
- noninvasive
- nonmalignant
- nonmetastatic
- nonprescription
- nonrandomized clinical trial
- nonsteroidal anti-inflammatory drug
- nonsteroidal aromatase inhibitor
- nontoxic
- normal range
- normative
- NP
- NPO
- NSAID
- nuclear grade
- nuclear magnetic resonance imaging
- nuclear medicine scan
- nurse
- nurse practitioner
- nutrition
- nutrition therapy
- nutritional counseling
- nutritional status
- nutritional supplement
- nutritionist
- obese
- objective improvement
- objective response
- observation
- observational study
- obstruction
- off-label
- olaparib
- oncologist
- oncology
- oncology nurse
- oncology pharmacy specialist
- oncolysis
- ondansetron
- onset of action
- oophorectomy
- open biopsy
- open label study
- open resection
- operable
- opiate
- opioid
- opportunistic infection
- oral
- organ
- orthodox medicine
- osteolytic
- osteonecrosis of the jaw
- osteopenia
- osteoporosis
- OTC
- out of network
- outcome
- outpatient
- ovarian
- ovarian ablation
- ovarian cancer
- ovarian suppression
- ovary
- over-the-counter
- overall survival rate
- overdose
- overexpress
- overweight
- ovulation
- PA
- paclitaxel
- paclitaxel albumin-stabilized nanoparticle formulation
- paclitaxel-loaded polymeric micelle
- Paget disease of the nipple
- pain threshold
- palliation
- palliative care
- palliative therapy
- palmar-plantar erythrodysesthesia
- palonosetron hydrochloride
- palpable disease
- palpation
- palpitation
- pamidronate
- panic
- papillary tumor
- Paraplatin
- parenteral nutrition
- paroxetine hydrochloride
- PARP
- PARP inhibitor
- partial-breast irradiation
- partial mastectomy
- partial oophorectomy
- partial remission or partial response
- pastoral counselor
- paternal
- pathologic fracture
- pathological stage
- pathological staging
- pathologist
- pathology report
- patient advocate
- Paxil
- peau d'orange
- pedigree
- peer-review process
- peer-reviewed scientific journal
- perfusion magnetic resonance imaging
- perimenopausal
- periodic neutropenia
- perioperative
- peripheral neuropathy
- peripheral venous catheter
- personal health record
- personal medical history
- personalized medicine
- Pertuzumab
- PET scan
- pharmacist
- phase I/II trial
- phase I trial
- phase II/III trial
- phase II trial
- phase III trial
- phase IV trial
- phlebotomy
- photon beam radiation therapy
- phyllodes tumor
- physical examination
- physical therapist
- physical therapy
- physician
- physician assistant
- physiologic
- PI3 kinase inhibitor
- pilocarpine
- pilot study
- placebo
- placebo-controlled
- plastic surgeon
- plastic surgery
- population study
- positive axillary lymph node
- positive test result
- positron emission tomography scan
- post-traumatic stress disorder
- postmenopausal
- postoperative
- postremission therapy
- potentiation
- power of attorney
- PR
- PR+
- PR-
- practitioner
- preauthorization
- precancerous
- preclinical study
- predictive factor
- pregabalin
- premalignant
- premature menopause
- premenopausal
- premium
- prescription
- prevention
- preventive
- preventive mastectomy
- primary care
- primary care doctor
- primary endpoint
- primary therapy
- primary treatment
- primary tumor
- Principal investigator
- prochlorperazine
- progesterone
- progesterone receptor
- progesterone receptor-negative
- progesterone receptor-positive
- progesterone receptor test
- progestin
- prognosis
- prognostic factor
- progression
- progression-free survival
- progressive disease
- Prolia
- proliferative index
- promegapoietin
- prophylactic
- prophylactic mastectomy
- prophylactic oophorectomy
- prophylactic surgery
- prophylaxis
- prospective
- prospective cohort study
- prosthesis
- protective factor
- protein
- protein-bound paclitaxel
- protein expression
- protein expression profile
- protocol
- proton
- proton magnetic resonance spectroscopic imaging
- pruritus
- psychiatrist
- psychological
- psychologist
- psychosocial
- psychotherapy
- PTSD
- pump
- punch biopsy
- qi
- qigong
- quadrantectomy
- quality assurance
- quality of life
- radiation
- radiation brachytherapy
- radiation dermatitis
- radiation fibrosis
- radiation necrosis
- radiation nurse
- radiation oncologist
- radiation physicist
- radiation surgery
- radiation therapist
- radiation therapy
- radical lymph node dissection
- radical mastectomy
- radioactive
- radioactive drug
- radioactive seed
- radioisotope
- radiologic exam
- radiologist
- radiology
- radionuclide
- radionuclide scanning
- radiopharmaceutical
- radiosensitization
- radiosensitizer
- radiosurgery
- radiotherapy
- raloxifene
- raloxifene hydrochloride
- randomization
- randomized clinical trial
- receptor
- RECIST
- reconstructive surgeon
- reconstructive surgery
- recreational therapy
- recurrence
- recurrent cancer
- referral
- reflexology
- refractory
- refractory cancer
- regimen
- regional
- regional anesthesia
- regional cancer
- regional chemotherapy